AC Immune (ACIU) Shares Outstanding (Weighted Average) (2014 - 2025)

AC Immune (ACIU) has 12 years of Shares Outstanding (Weighted Average) data on file, last reported at $127.3 million in Q4 2025.

• Quarterly Shares Outstanding (Weighted Average) rose 11.06% year-over-year to $127.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $127.3 million (up 11.06% YoY) and the FY2025 annual result came in at $122.7 million, up 7.06% from the prior year.
• Shares Outstanding (Weighted Average) retreated to $127.3 million in Q4 2025 per ACIU's latest filing, from $2.8 billion in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $2.8 billion in Q3 2025 and bottomed at $86.7 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $1.9 billion (2023), against an average of $1.6 billion.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) declined 10.84%; it then advanced 25.48% in 2024.
• Tracing ACIU's Shares Outstanding (Weighted Average) over 5 years: stood at $97.3 million in 2021, then fell by 10.84% to $86.7 million in 2022, then increased by 10.09% to $95.5 million in 2023, then climbed by 20.05% to $114.6 million in 2024, then climbed by 11.06% to $127.3 million in 2025.
• Per Business Quant, the three latest ACIU Shares Outstanding (Weighted Average) figures stand at $127.3 million (Q4 2025), $2.8 billion (Q3 2025), and $2.7 billion (Q2 2025).

Peer Comparison